Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome‐positive acute lymphoblastic leukemia

Tyrosine kinase inhibitor (TKI) administration after allogeneic hematopoietic stem cell transplantation (HSCT) may carry a survival benefit in Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ ALL). Therefore, we investigated whether TKI prophylaxis for negative‐minimal residual dis...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Sci
Autors principals: Akahoshi, Yu, Nishiwaki, Satoshi, Mizuta, Shuichi, Ohashi, Kazuteru, Uchida, Naoyuki, Tanaka, Masatsugu, Fukuda, Takahiro, Ozawa, Yukiyasu, Takahashi, Satoshi, Onizuka, Makoto, Shiratori, Souichi, Nakamae, Hirohisa, Kanda, Yoshinobu, Ichinohe, Tatsuo, Atsuta, Yoshiko, Kako, Shinichi
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2019
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6778639/
https://ncbi.nlm.nih.gov/pubmed/31402561
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14167
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars